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ABSTRACT
OBJECTIVES
To determine the clinical effectiveness and cost 
effectiveness of including emollient bath additives in 
the management of eczema in children.
DESIGN
Pragmatic randomised open label superiority trial with 
two parallel groups.
SETTING
96 general practices in Wales and western and 
southern England.
PARTICIPANTS
483 children aged 1 to 11 years, fulfilling UK 
diagnostic criteria for atopic dermatitis. Children with 
very mild eczema and children who bathed less than 
once weekly were excluded.
INTERVENTIONS
Participants in the intervention group were prescribed 
emollient bath additives by their usual clinical team 
to be used regularly for 12 months. The control 
group were asked to use no bath additives for 12 
months. Both groups continued with standard eczema 
management, including leave-on emollients, and 
caregivers were given standardised advice on how to 
wash participants.
MAIN OUTCOME MEASURES
The primary outcome was eczema control measured by 
the patient oriented eczema measure (POEM, scores 
0-7 mild, 8-16 moderate, 17-28 severe) weekly for 16 
weeks. Secondary outcomes were eczema severity 
over one year (monthly POEM score from baseline 
to 52 weeks), number of eczema exacerbations 
resulting in primary healthcare consultation, 
disease specific quality of life (dermatitis family 
impact), generic quality of life (child health utility-
9D), utilisation of resources, and type and quantity 
of topical corticosteroid or topical calcineurin 
inhibitors prescribed.
RESULTS
483 children were randomised and one child was 
withdrawn, leaving 482 children in the trial: 51% 
were girls (244/482), 84% were of white ethnicity 
(447/470), and the mean age was 5 years. 96% 
(461/482) of participants completed at least one 
post-baseline POEM, so were included in the analysis, 
and 77% (370/482) completed questionnaires for 
more than 80% of the time points for the primary 
outcome (12/16 weekly questionnaires to 16 weeks). 
The mean baseline POEM score was 9.5 (SD 5.7) in 
the bath additives group and 10.1 (SD 5.8) in the no 
bath additives group. The mean POEM score over the 
16 week period was 7.5 (SD. 6.0) in the bath additives 
group and 8.4 (SD 6.0) in the no bath additives group. 
No statistically significant difference was found in 
weekly POEM scores between groups over 16 weeks. 
After controlling for baseline severity and confounders 
(ethnicity, topical corticosteroid use, soap substitute 
use) and allowing for clustering of participants within 
centres and responses within participants over time, 
POEM scores in the no bath additives group were 
0.41 points higher than in the bath additives group 
(95% confidence interval −0.27 to 1.10), below the 
published minimal clinically important difference 
for POEM of 3 points. The groups did not differ 
in secondary outcomes, economic outcomes, or 
adverse effects.
CONCLUSIONS
This trial found no evidence of clinical benefit from 
including emollient bath additives in the standard 
management of eczema in children. Further research 
is needed into optimal regimens for leave-on 
emollient and soap substitutes.
TRIAL REGISTRATION
Current Controlled Trials ISRCTN84102309.
Introduction
Childhood eczema (also known as atopic eczema or 
atopic dermatitis) is a common condition that can 
have a substantial impact on quality of life for children 
and their families.1 Guidelines suggest that complete 
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WhAT IS AlReAdy knoWn on ThIS TopIC
There are three methods of application of emollients; leave-on emollients, soap 
substitutes and emollient bath additives
Although evidence supports the use of leave-on emollients and there is clinical 
consensus around soap substitutes, less agreement exists about the benefits of 
emollient bath additives to treat eczema in children
The effectiveness of emollient bath additives to treat childhood eczema has not 
been assessed owing to a lack of adequately powered trials
WhAT ThIS STudy AddS
This large, pragmatic randomised controlled trial of children with eczema (aged 
1-11 years) found no evidence of a clinically meaningful benefit from emollient 
bath additives, when used in addition to standard eczema management
Questions remain about optimal regimens for leave-on treatments, soap 
substitutes, and frequency of bathing in eczema treatment
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emollient therapy forms the mainstay of treatment 
for eczema and should be used regularly with topical 
corticosteroids or topical calcineurin inhibitors, used 
in addition for flare-ups.2
Emollients are thought to act by providing a barrier 
over the skin, decreasing moisture loss, and protecting 
against skin irritants. Emollients are applied in one 
of three ways: leave-on, where emollients are directly 
applied to the skin; soap substitutes, where emollients 
are used instead of soap or other wash products; and 
bath additives, comprising oil or emulsifiers, or both 
designed to be added to bath water and thought to 
leave a film of oil over the skin. Some emollients can 
be used in more than one way. We therefore use the 
term “emollient bath additives” or “bath additives” 
rather than bath emollients to emphasise the 
differences between the three methods of application 
in recognition that products may have more than one 
method of application.
Although there is evidence for the need for leave-on 
emollients3 and widespread clinical consensus around 
soap substitutes, there is less agreement about the 
potential additional benefits of bath additives4 and a 
dearth of evidence on their effectiveness. Systematic 
reviews have found no evidence of effectiveness, 
and one small study suggested bath additives might 
actually worsen eczema outcomes.5 Bath additives 
are, however, widely prescribed at a cost of more than 
£23m ($33m; €26m) annually to the National Health 
Service in England.6
We determined both the clinical effectiveness and 
the cost effectiveness of including emollient bath 
additives in the standard management of eczema in 
children.
Methods
This was a pragmatic, multicentre, randomised open 
label superiority trial with two parallel groups allocated 
in a 1:1 ratio comparing emollient bath additives 
in addition to standard eczema care compared with 
standard care alone for childhood eczema. We chose 
a pragmatic design7 that aimed to test whether bath 
additives offer additional benefit in real life eczema 
care rather than in ideal experimental conditions. 
The study was registered before recruitment of the 
first participant, and the study protocol has been 
published.8
Children eligible for the trial were aged 1 to 11 
years and fulfilled UK diagnostic criteria for atopic 
dermatitis.9 We excluded children with inactive or very 
mild eczema over the past 12 months, defined as a 
score of 5 or less on the Nottingham eczema severity 
scale (scale from 3 to 15, where 3 to 8 is mild, 9 to 11 is 
moderate, and 12 to 15 is severe).10 We also excluded 
children who usually bathed less than once a week or 
whose carers were not willing to accept randomisation. 
Only one child was enrolled in each family.
Participants were recruited from 96 general practices 
in Wales and the west and south of England. We used 
the practices’ medical records to identify children with 
a recorded diagnosis of eczema and who had received 
one or more prescriptions for eczema in the past 12 
months. General practice staff also recruited potential 
participants opportunistically. Parents or carers were 
asked to return a reply slip to the study team. A brief 
screening questionnaire included the UK diagnostic 
criteria for atopic dermatitis and the Nottingham 
eczema severity scale. A researcher telephoned parents 
or carers who expressed an interest in the study to 
confirm likely eligibility of children and to arrange a 
baseline appointment. Informed consent was sought 
at this time and baseline questionnaires completed. 
Subsequent questionnaires were completed online or 
by post with no further face-to-face contact between 
the participants and the trial team. Informed consent 
was received for trial participants before enrolment.
Interventions
Participants in the intervention group were prescribed 
bath additives by their general practice and were 
asked to use them regularly for 12 months. We 
encouraged practices to issue the three bath additives 
most commonly prescribed in the UK: Oilatum (Glaxo 
SmithKline; 63% light liquid paraffin), Balneum 
(Allmarall; 85% soya oil), or Aveeno (Johnson & 
Johnson; no summary of product characteristics 
available). Other bath additives could be issued, with 
the exception of products containing antimicrobials, 
which we excluded as they have been shown to have 
a greater irritant effect than other bath additives.11 
The control group were not prescribed bath additives 
and were asked not to use any bath additives for 
12 months. Both groups were given standardised 
written advice on how to wash, including the use of 
leave-on emollient as a soap substitute. Both groups 
were advised to continue with standard eczema 
management, including regular leave-on emollients 
and topical corticosteroids when required. Ongoing 
clinical care was otherwise unchanged.
Outcomes
The primary outcome was eczema severity measured by 
the patient oriented eczema measure (POEM) reported 
by parents or carers weekly over 16 weeks.12  13 The 
POEM is a patient reported outcome, which scores 
symptoms over the previous week. It consists of seven 
questions that can be completed by the child’s parent 
or carer and provides a severity score on a scale from 
0 to 28, where 0 to 2 is clear or almost clear, 3 to 7 is 
mild, 8 to 16 is moderate, and 17 to 28 is severe.11 The 
published minimal clinically important difference of 
the POEM is 3 points.14 15 POEM was the only patient 
reported outcome measure for eczema to show validity 
and repeatability in a systematic review and has been 
adopted as the preferred patient reported outcome 
measure for eczema symptoms internationally.16 17
The relapsing and remitting course of eczema means 
that repeated measures are a better reflection of effect 
than follow-up assessment at a single time point.
Secondary outcomes included eczema severity 
measured by POEM every four weeks from baseline 
to 52 weeks; disease specific quality of life at 16 
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weeks and one year, measured by dermatitis family 
impact18; generic quality of life at 16 weeks and one 
year, measured by child health utility-9D19; number 
of eczema exacerbations resulting in a primary 
healthcare consultation over one year (review of 
general practitioners’ (GPs’) notes); type (strength) 
and quantity of topical corticosteroid or topical 
calcineurin inhibitors prescribed over one year (review 
of GPs’ notes); resource use from parent or carer 
questionnaires and review of GPs’ notes; and other 
outcomes: adherence to treatment allocation (parent 
or carer report), and adverse effects, such as stinging, 
redness, slipping in the bath, or refusal to bathe 
(parent or carer report).
Sample size
The sample size was calculated for repeated measures 
analysis of variance in weekly POEM scores over 16 
weeks. Using weekly data from a similar population in 
the Softened Water Eczema Trial (SWET),20 we aimed 
to detect a mean difference of 2.0 (SD 7.0) points 
between intervention and control groups. Although the 
published minimal clinically important difference for 
POEM is 3 points,14 15 we sought to detect a difference 
of 2 owing to the expectation of low POEM scores at 
baseline in a population recruited entirely through 
primary care. An α of 0.05 and power of 0.9, with a 
correlation between repeated measures of 0.70, gave a 
sample size of 338. Allowing for 20% loss to follow-up 
gave a total sample size of 423 participants.
Early data showed adherence to treatment allocation 
was achieved by approximately 80% of participants in 
both groups. Therefore, to allow a per protocol analysis 
with 90% power, in addition to the primary intention 
to treat analysis, we sought and obtained approval for 
an ethics amendment requesting permission to recruit 
an additional 68 participants, giving a revised target 
of 491 participants. No other changes to protocol 
occurred.
Randomisation
Participants who provided consent were randomly 
allocated in 1:1 ratio to the intervention or 
control groups, stratified by coordinating centre 
(Southampton, Bristol, Cardiff). Randomisations were 
conducted at the end of the recruitment appointment, 
following completion of consent and the baseline 
questionnaire so that treatment allocation could not 
be known before study entry.
Randomisation was carried out using LifeGuide 
software hosted at the University of Southampton 
and automated to ensure concealment. As baseline 
appointments were sometimes remote from internet 
access, a back-up randomisation system involved 
phoning the trial manager. The unique participant 
identifier was then entered into a spreadsheet that 
allocated treatment on a 1:1 ratio, stratified by 
coordinating centre, from an MS Excel spreadsheet 
preprogrammed by the trial statistician. Thirty 
randomisations were conducted using this offline 
method.
It was not possible to make a convincing placebo 
for emollient bath additives, which add a greasy film 
to water, and participating families were therefore 
not blind to treatment allocation. As all outcomes 
were either reported by participants or collected on 
a clinical record review template, we did not mask 
clinical study officers or research nurses to allocation. 
Statisticians carrying out the analyses were blind to 
treatment allocation.
Statistical analysis
Analysis was conducted according to CONSORT 
guidelines, following an analysis plan agreed 
in advance with the independent trial steering 
committee. We used descriptive statistics to compare 
baseline characteristics of trial participants by 
allocated group. The primary analysis for the total 
POEM score was performed using a multilevel mixed 
model framework with observations over time from 
weeks 1 to 16 (level  1) nested within participants 
(level 2). Our primary outcome is based on adjusted 
results, controlling for baseline POEM score, recruiting 
centre, and any significant confounders. We also report 
unadjusted results.
For all models, we analysed participants in the 
group to which they were randomised, regardless of 
their adherence to that allocation (intention to treat 
analysis). The only exception to this was the per 
protocol analysis, where analyses were carried out on 
the basis of bath additive use as reported by parents 
or carers.
The model used all the observed data and we 
made the assumption that missing POEM scores are 
missing at random given the observed data. The model 
included a random effect for centre (random intercept) 
and patient (random intercept and slope on time) to 
allow for differences between patients and between 
centres at baseline and between patients in the rate of 
change over time (if a treatment or time interaction was 
significant), and fixed effects for baseline covariates. 
We used an unstructured covariance matrix.
In the analysis of secondary outcomes, for the 
monthly POEM measure up to one year we used 
repeated measures analysis in line with that used for 
the primary outcome. For other secondary outcomes, 
we used linear regression for continuous outcomes if 
the assumptions were met. Otherwise we used non-
parametric analyses. We used logistic regression for 
dichotomous outcomes and a suitable count model, as 
determined by goodness of fit measures, for count data. 
In all analyses we controlled for stratification variables 
and potential confounders. As set out in the statistical 
analysis plan, we carried out preplanned sensitivity 
analysis and exploratory subgroup analyses. For the 
economic evaluation we used resource use, cost and 
effectiveness data collected from participants, and 
reviews of GPs’ notes.
Patient and public involvement
The James Lind Alliance Priority Setting Partnership 
for Eczema top 10 included priorities around bathing 
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and washing and around the best ways to use 
emollients.21 This trial was funded following a topic 
suggestion form submitted through the National 
Institute for Health Research website, leading to a 
commissioned call.
The trial management group included an 
experienced patient and public involvement 
(PPI) co-applicant (AR) who participated in all 
phases of the trial design, including planning 
recruitment and recruitment materials. We also 
consulted members of the Centre of Evidence 
Based Dermatology patient panel at the trial design 
stage, and we sought additional PPI representation 
when planning how to disseminate findings. The 
independent trial steering committee included a 
PPI member. The results will be emailed to all trial 
participants and published on the trial website. The 
burden of the intervention was minimal, with many 
families already familiar with using bath additives 
with no difficulty.
Usual care with no bath additive (n=218)Usual care with bath additive (n=265)
Analysed (n=209)Analysed (n=252)
Invited (n=12 504)
Assessed for eligibility (n=1447)
Randomised (n=483)
Lost to follow-up (n=9):
  No post-baseline measures completed (n=9)
  Withdrawn (n=0)
Lost to follow-up (n=13):
  No post-baseline measures completed (n=12)
  Withdrawn, all data removed (n=1)
Excluded (n=964):
  Declined to participate (n=527)
  Did not meet inclusion criteria (n=200)
  Other reasons (n=237)
Fig 1 | Flow of participants through trial
Table 1 | Baseline characteristics of trial participants. Values are numbers (percentages) unless stated otherwise
Characteristics Bath additives (n=264) No bath additives (n=218) Total (n=482)
Mean (SD) age (years) 5.4 (2.9) 5.2 (2.9) 5.3 (2.9)
Sex: n=264 n=218 n=482
 Boys 138 (52) 100 (46) 238 (49)
 Girls 126 (48) 118 (54) 244 (51)
Mean (SD) age of carers (years) 36.5 (6.5) 35.9 (6.7) 36.2 (6.5)
Sex of carers: n=258 n=212 n-470
 Male 11 (4) 12 (6) 23 (5)
 Female 247 (96) 200 (94) 447 (95)
Ethnicity: n=257 n=215 n=472
 White 228 (86) 176 (82) 397 (84)
 Black 6 (2) 9 (4) 15 (3)
 Asian 15 (6) 16 (7) 31 (7)
 Mixed race 10 (4) 9 (4) 19 (4)
 Chinese 2 (1) 3 (1) 5 (1)
 Other 3 (1) 2 (1) 5 (1)
Highest qualification: n=257 n=213 n=470
 Not answered 6 (2) 3 (1) 9 (2)
 Degree or equivalent 106 (41) 90 (42) 197 (42)
 Diploma or equivalent 56 (22) 37 (17) 95 (20)
 A level 25 (10) 24 (11) 49 (10)
 GSCE or O level 50 (19) 38 (18) 88 (19)
 Other 12 (5) 16 (8) 29 (6)
 None 2 (1) 5 (2) 7 (1)
Cost of living: n=257 n=213 n=470
 Not answered 6 (2) 3 (1) 9 (2)
 Finding it a strain 11 (4) 3 (1) 14 (3)
 Have to be careful 105 (41) 82 (38) 187 (40)
 Able to manage 99 (39) 90 (42) 189 (40)
 Quite comfortable 35 (14) 35 (16) 70 (15)
Prior belief in bath additives (1-9)* 5.1 (2) 4.8 (2) 5.0 (2)
Mean (SD) POEM score (0-28) 9.5 (5.7) 10.1 (5.8) 9.8 (5.8)
POEM scores†: n=264 n=218 n=482
 Mild (0-7) 114 (43) 73 (33) 187 (39)
 Moderate (8-16) 119 (45) 114 (52) 233 (48)
 Severe (17-28) 31 (12) 31 (14) 62 (13)
Median (IQR) DFIQ score (0-30) 2 (1-6) 3 (1-7) 3 (1-7)
Mean (SD) NESS score (3-15) 9.5 (2.3) 9.5 (2.3) 9.5 (2.3)
Mean (SD) CHU-9D score (utility values) 0.90 (0.1) 0.90 (0.1) 0.90 (0.1)
*Where 1 is not at all effective and 9 is very effective.
†461/482 (96%) participants had completed at least one POEM after baseline and were included in the primary analysis, and 77% (370/482) 
completed more than 80% of time points for the primary outcome (12/16 weekly questionnaires to 16 weeks).
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Results
Participants were recruited between December 2014 
and May 2016. Invitations were sent to the parents 
or carers of 12 504 children and 1451 responses 
were received. Of these, 920 expressed a willingness 
to be contacted and included a completed screening 
questionnaire. Overall, 662 met the eligibility criteria 
and were approached regarding participation, and 483 
entered the trial. One carer subsequently withdrew 
permission, therefore analysis was carried out on data 
from 482 participants (n=264 intervention group, 
n=218 control group, fig 1).
Table 1 shows the characteristics of trial participants 
These were well balanced at baseline, although more 
participants were allocated to the bath additives group 
than to the no bath additives group.
Parent or carer report of adherence to treatment 
allocation group at 16 weeks showed that 93% 
(216/233) of participants in the bath additives group 
used bath additives every time or more than half the 
time. Of those in the no bath additives group, 92% 
(176/191) said they used bath additives either never 
or less than half the time (table 2).
For frequency of bathing, parent or carer reports 
showed that 31% (124/397) of participants had fewer 
than three baths a week, 33% (130/397) had three 
or four baths a week, and 36% (143/397) had five or 
more baths a week.
Of participants allocated to receive bath additives, 
45% (120/265) received Oilatum bath additive, 26% 
(68/265) Aveeno bath oil, 4.5% (12/265) Balneum 
bath oil, and 30% (79/265) another bath additive (14 
received more than one different bath additive during 
the study).
The baseline POEM score was 9.5 (SD 5.7) in the 
bath additives group and 10.1 (SD 5.8) in the no bath 
additives group. The mean POEM score over the 16 
week period was 7.5 (SD 6.0) in the bath additives 
group and 8.4 (SD 6.0) in the no bath additives group 
(fig 2). No statistically significant difference was found 
in weekly POEM scores between the two groups over the 
16 week period. After controlling for baseline severity 
and confounders (ethnic group, topical corticosteroid 
use, and soap substitute use) and allowing for the 
clustering of participants within centres and responses 
within participants over time, the POEM score in the 
no bath additives group was 0.41 points higher than 
in the bath additives group (95% confidence interval 
−0.27 to 1.10), which is substantially lower than the 
published minimal clinically important difference of 3 
points.14 15
Secondary analyses for differences between groups 
based on adherence to treatment allocation (per 
protocol analysis) similarly showed no statistically 
significant difference between the groups on POEM 
repeated measures over 16 weeks: “More than half” or 
“every time” versus “less than half the time” or “never” 
adjusted difference in mean POEM scores 0.32 (95% 
confidence interval −0.37 to 1.02).
No significant differences were found between groups 
in any of the secondary outcomes, such as POEM score 
over 52 weeks (adjusted difference in mean POEM 
score 0.75, 95% confidence interval −0.05 to 1.55), 
dermatitis family impact, generic quality of life (child 
health utility-9D), number of eczema exacerbations, 
and type or quantity of topical corticosteroid or 
topical calcineurin inhibitors prescribed over one year 
(table 3).
Prespecified exploratory subgroup analyses 
suggested the possibility of a small effect of bath 
additives among children aged less than 5 years, 
with the adjusted mean POEM score in the no bath 
additives group 1.29 (95% confidence interval 0.33 to 
2.25) points higher than in the bath additives group. 
However, the upper limit of the confidence interval 
is below the now widely accepted POEM minimal 
clinically important difference of 3 points.
A statistically significant interaction effect was 
also seen by frequency of bathing as reported at 16 
weeks. No statistically significant difference was found 
between children who bathed one to four times a 
week. In those who bathed five or more times a week, 
however, the POEM score was 2.27 points higher (0.63 
to 3.91) in the no bath additives group. The upper 
confidence interval suggests there might be a small 
clinically meaningful benefit to bath additives in this 
group. But this group has only 77 in the bath additives 
group and 66 in the no bath additives group (table 4). 
No apparent difference was found in outcomes for 
those with moderate or severe eczema.
Adverse effects were noticeably similar in both 
groups, despite slips in the bath, stinging, or redness 
Table 2 | Adherence to allocated treatment and frequency of bathing during 16 week 
primary outcome period. Values are numbers (percentages)
Treatment allocation Bath additives No bath additives
Use of bath additives: (n=233) (n=191)
 Every time 172 (74) 14 (7)
 >50% of the time 44 (19) 1 (0.5)
 <50% of the time 15 (6) 9 (5)
 Never 2 (1) 167 (87)
No of baths per week: (n=221) (n=176)
 1-2 70 (32) 54 (31)
 3-4 74 (33) 56 (32)
 5-6 45 (20) 39 (22)
 ≥7 32 (14) 27 (15)
Week
M
ea
n 
PO
EM
 s
co
re
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
0
4
8
12
24
28
16
20
No bath additives
Bath additives
Fig 2 | Patient oriented eczema measure (POEM) scores 
during 16 week primary outcome period
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being common side effects reported in the summary 
of product characteristics for emollient bath additives. 
Over the first 16 weeks, 35% in the bath additives 
group and 35% in the no bath additives group reported 
at least one adverse event on weekly questionnaires 
(table 5), with no statistically significant difference 
between the groups (odds ratio 1.40, 95% confidence 
interval 0.79 to 2.47).
For the economic evaluation we followed a 
prespecified analysis plan and explored resource 
utilisation from the perspective of the national health 
service and family. The mean annual costs to the NHS 
were estimated at £180.50 (SD £237.0) for the bath 
additives group and £166.12 (SD £293.0) for the no 
bath additives group. The annual results for quality 
of life years were 0.91 (SD 0.1) for the bath additives 
group and 0.90 (SD 0.1) for the no bath additives 
group. The difference in cost means was £14.38 (95% 
confidence interval −£33.45 to £62.21) and in quality 
adjusted life years means was 0.00 (−0.01 to 0.02). 
The costs borne by families showed an annual higher 
spend within the no bath additives group of £51.37 
(95% confidence interval −£15.74 to £118.49) and the 
adjusted difference was £47.56 (−£18.07 to £113.19), 
none of which were statistically significant. For the 
economic analysis we found no benefits that could 
be used to consider the intervention cost effective. 
Full data on resource use (review of GPs’ notes and 
parent or carer report) and cost effectiveness analysis 
will be published in the National Institute for Health 
Research health and technology assessment journals 
library.
Table 3 | Secondary outcomes by treatment allocation
Outcomes Bath additives No bath additives
Difference (95% CI)
Univariate Adjusted
Mean (SD) repeated monthly measures over 52 weeks 7.3 (6.3) 8.4 (6.4) 0.99 (0.03 to 1.96) 0.75 (−0.05 to 1.55)
Median (interquartile range) disease specific quality of life:
 Baseline 2 (1-6) 3 (1-7)
 16 weeks 2 (0-5) 3 (1-7) 1.00 (0.09 to 1.91) 0.29 (−0.57 to 1.14)
 52 weeks 2 (0-5) 2 (0-6) 0.00 (−0.93 to 0.93) −0.29 (−1.36 to 0.79)
Mean (SD) generic quality of life*:
 Baseline 0.90 (0.1) 0.90 (0.1) 0.00 (−0.02 to 0.02)
 16 weeks 0.91 (0.1) 0.89 (0.1) 0.01 (−0.01 to 0.03)
 52 weeks 0.90 (0.1) 0.91 (0.1) −0.01 (−0.03 to 0.01)
Total No of TCS/TCI prescriptions 325 346
Median (interquartile range) No of TCS/TCI prescriptions 0 (0-2) 1 (0-3)
Median (interquartile range) No of exacerbations 1 (0-2) 1 (0-3) 1.33 (1.02 to 1.75)† 1.24 (0.96 to 1.60)†
TCS=topical corticosteroid; TCI=topical calcineurin inhibitor.
*Child health utility-9D.
†Relative risk (95% CI).
Table 4 | Patient oriented eczema measure (POEM) scores during 16 week primary outcome period, by group and subgroup
Repeated measures No (%)
Mean (SD)
Interaction term (95% CI)
Adjusted difference in mean  
POEM score* (95% CI)Bath additives No bath additives
Age (years):
 <5 256 (53) 6.99 (5.67) 9.09 (6.01) −1.43 (−2.02 to −0.15) 1.29 (0.33 to 2.25) ≥5 226 (47) 7.97 (6.24) 7.52 (5.92) −0.29 (−1.21 to 0.63)
Baseline eczema severity:
 Mild (0-7) 187 (39) 4.78 (4.26) 5.22 (4.58)
−0.05 (−1.14 to 1.05)
−0.07 (−1.08 to 0.95)
 Moderate (8-16) 233 (48) 8.14 (5.54) 9.18 (5.46) 0.65 (−0.45 to 1.74)
 Severe (17-28) 62 (13) 14.63 (6.16) 13.03 (6.92) −1.16 (−3.62 to 1.32)
Use of leave-on emollient weekly:
 0-4 days 138 (29) 7.64 (6.68) 6.43 (5.42) −0.02 (−2.05 to 2.01) 0.26 (−1.34 to 1.86) 5-7 days 344 (71) 8.61 (5.74) 7.93 (6.14) 0.69 (−0.39 to 1.76)
Topical corticosteroid use:
 Any 241 (51) 8.40 (6.19) 9.35 (6.21) 0.52 (−1.35 to 2.40) 1.22 (−0.18 to 2.63) None 234 (49) 6.63 (5.64) 7.39 (5.66) 0.58 (−0.64 to 1.81)
Frequency of bathing at 16 weeks:
 1-4 times/week 255 (64) 7.93 (5.94) 8.00 (5.82) 2.14 (0.21 to 4.07) −0.26 (−1.38 to 0.87) ≥5 times/week 143 (36) 6.30 (5.70) 8.75 (6.12) 2.27 (0.63 to 3.91)
Prior belief in bath additives:
 Low (1-3) 106 (29) 7.93 (6.10) 9.27 (6.25)
0.85 (−0.52 to 2.21)
1.17 (−0.78 to 3.13)
 Moderate (4-6) 158 (44) 8.37 (6.06) 8.68 (6.02) −0.16 (−1.77 to 1.45)
 High (7-9) 97 (27) 5.70 (5.06) 7.09 (6.05) 1.80 (0.04 to 3.56)
Use of soap substitute at 16 weeks:
 Any 89 (21) 8.09 (6.10) 9.31 (5.88)
1.30 (−0.97 to 3.57)
1.72 (−0.44 to 3.88)
 None 340 (79) 7.17 (5.82) 7.99 (5.87) 0.36 (−0.63 to 1.35)
*Adjusted for baseline severity, ethnic group, steroid use, and soap substitute use and allowing for clustering of patients within centres and responses within patients over time.
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discussion
This trial provides strong evidence that emollient bath 
additives provide minimal or no additional benefit 
beyond standard eczema care in the management of 
eczema in children.
The BATHE trial was an adequately powered trial, 
with high follow-up rates and good adherence to trial 
intervention allocations. The study has strong external 
validity as it was pragmatic in design to reflect normal 
practice, and, despite the relatively low response rate, 
participants were broadly reflective of children with 
eczema seen in primary care. We used a participant 
reported outcome measure with good validity that 
has been accepted by international consensus.15 A 
participant reported outcome could be biased in favour 
of finding a positive effect of trial intervention owing 
to a perception of benefits of treatment. However, the 
negative result of the trial suggests that this was not 
the case.
This trial was large; previous reviews of the literature 
have not been able to draw conclusions owing to the 
small size of existing trials.5
We cannot exclude the possibility of a small benefit 
among children bathing more than five times a week or 
among children aged less than 5 years, but differences 
are sufficiently small to be unlikely to be clinically 
useful. Furthermore, caution is needed in interpreting 
these underpowered subgroup analyses as statistically 
significant results might arise because the data have 
been tested multiple times rather than because a 
genuine difference exists between the groups.
These findings are timely for clinicians and 
prescribing advisers, as prescribing guidelines vary 
widely in their advice on the use of bath additives,22 
and pressure on budgets has led to formularies 
becoming increasingly restrictive. Reviews have 
estimated that bath additives might contribute to 
up to one third of the costs of eczema in the United 
Kingdom.4 Our findings provide evidence that can 
contribute to effective prescribing in this area, where 
there is currently little research evidence to guide 
decision making. These findings are also useful for 
families with members who have eczema as they have 
more certainty about directing their efforts towards 
more effective treatments.
Our findings are only relevant to the use of emollient 
bath additives. More research is needed into optimal 
regimens for other emollients, although there is strong 
evidence that regular use of leave-on emollients 
prevents flare-ups in eczema,3 and there is widespread 
clinical consensus around the role of emollients as 
soap substitutes.
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